Second chance: Liposome-Wrapped chemo targets tough leukemia

NCT ID NCT04049539

First seen Apr 13, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study is for people with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. It tests a drug called Vyxeos, which combines two chemotherapy drugs (cytarabine and daunorubicin) inside a tiny fat bubble (liposome) to deliver them more effectively and with fewer side effects. The goal is to see if Vyxeos can control the disease and improve survival in these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

  • UC Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.